To compare the safety and efficacy of fast-acting insulin aspart (faster aspart) with conventional insulin aspart (IAsp) in adults with type 1 diabetes (T1D).
formations and delivery methods that accelerate both insulin absorption and action profile. [8] [9] [10] [11] [12] [13] [14] Fast-acting insulin aspart (faster aspart) is a new formulation of IAsp (NovoRapid/NovoLog, Novo Nordisk A/S, Bagsvaerd, Denmark) containing niacinamide; data suggest this promotes formation of IAsp monomers after subcutaneous injection, 15 leading to more rapid absorption of faster aspart into the bloodstream vs conventional
IAsp. 16 In a pooled analysis of six randomized trials in participants with type 1 diabetes (T1D; n = 218), onset of appearance was twice as fast and early insulin exposure 2-fold greater, leading to a 74% greater early glucose-lowering effect with faster aspart vs IAsp. 16 The phase III onset 1 trial evaluated efficacy and safety of faster aspart as part of a basal-bolus regimen in T1D. 17 At 26 weeks, non-inferiority of mealtime faster aspart to mealtime IAsp was confirmed in terms of HbA1c change. 17 Compared with IAsp, faster aspart resulted in a significantly greater reduction in HbA1c, and provided superior mealtime PPG control, with no difference in overall rate of severe or blood glucose (BG)-confirmed hypoglycaemia.
Long-term follow-up data are helpful when judging the clinical value of new treatments; therefore, onset 1's initial 26-week treatment period was followed by an additional 26-week treatment period, the aim of which was to assess the long-term safety and efficacy of faster aspart. In the present paper, we report the results for 52 weeks of treatment. Participants were adults (aged ≥18 years) with clinically diagnosed T1D who received treatment with a basal−bolus insulin regimen for ≥12 months before screening (including any regimen of IDet or insulin glargine for ≥4 months before screening), had HbA1c levels ranging from 53 to 80 mmol/mol (7.0%-9.5%) and body mass index ≤35.0 kg/m 2 . Key exclusion criteria were: any use of antidiabetic drugs other than insulin within the 3 months pre-screening; anticipated change in concomitant medications that interfere with glucose metabolism; cardiovascular disease within 6 months pre-screening; recurrent severe hypoglycaemia (>1 event during the previous 12 months); and hypoglycaemic unawareness (judged by investigators). Full exclusion criteria have been published previously. 17 
| Randomization and masking
Randomization was performed by the trial sponsor. At the randomization visit, participants with HbA1c ≤80 mmol/mol (9.5%) were randomly allocated 1:1:1 to receive double-blind pre-meal faster aspart
or IAsp or open-label post-meal faster aspart using a telephone or web-based randomization system. Randomization was stratified by:
method used for adjusting bolus insulin (i.e. carbohydrate counting or dosing algorithm); current basal treatment regimen (once or twice daily); and inclusion in the exploratory subgroup for continuous glucose monitoring and frequently sampled meal test (yes/no). 17 During the additional 26-week period, the blinded treatment allocation continued for the two mealtime arms. The investigator and participants remained blinded, but the sponsor was not blinded during the additional treatment period because the treatment randomization was unblinded to the sponsor for data analysis after the initial 26-week period.
| Procedures
The basal insulin provided throughout the study was IDet (100 U/ mL; 3. All bolus injections of faster aspart and IAsp were provided as 100 U/mL and administered 0-2 minutes before meals using a 3.0 mL were recorded daily for titration purposes.
Participants completing the run-in received a bolus dose of IAsp 
| Outcomes
The primary endpoint (change in HbA1c from baseline) and all confirmatory endpoints for onset 1 were reported after 26 weeks. 
| Statistical analysis
All analyses were conducted with SAS (version 9.4) software. The sample-size calculation has been reported previously. 17 Efficacy data were summarized from the full analysis set (FAS), which included all participants randomly allocated to treatment. Safety data were summarized from the safety analysis set, which included all participants receiving at least 1 dose of trial medication. All analyses were undertaken with the FAS. Changes in HbA1c level from baseline were analysed using a mixed-effect model for repeated measurements.
Responder endpoints (for HbA1c and PPG levels based on SMPG)
were analysed separately using a logistic regression model. Changes from baseline in mean 7-9-7-point SMPG profiles, mean PPG levels (two separate endpoints based on meal test and 7-9-7-point SMPG profile) and mean PPG increments (two separate endpoints based on meal test and 7-9-7-point SMPG profile), 1,5-AG, FPG and body weight were analysed using a mixed-effect model for repeated measurements similar to that used for HbA1c. The numbers of overall treatment-emergent severe or BG-confirmed hypoglycaemic episodes were analysed using a negative binomial regression model. No interim analyses were performed during the trial and a Novo Nordisk safety committee performed ongoing safety surveillance during the trial.
Further details of statistical methods are included in the Supporting Information.
| RESULTS
Between August 26, 2013 and June 11, 2015, participants were randomly allocated to mealtime faster aspart (n = 381) or mealtime IAsp (n = 380). Baseline characteristics were similar between treatment arms ( Table 1 ). The full 52-week trial was completed by 675 participants ( Figure S2 in File S1).
During run-in, observed mean HbA1c was reduced from 64.0 mmol/mol (8.0%) to 59.7 mmol/mol (7.6%) for participants subsequently randomized to receive mealtime faster aspart, and from 64.0 mmol/mol (8.0%) to 59.3 mmol/mol (7.6%) for participants subsequently randomized to receive mealtime IAsp (Figure 1 ). During the initial 26 weeks, observed mean HbA1c was reduced from baseline to 56.4 mmol/mol (7.3%) with faster aspart and to 57.6 mmol/mol (7.4%) with IAsp.
17
At 52 weeks, observed mean HbA1c was 58.5 mmol/mol (7.5%) with faster aspart and 59.6 mmol/mol (7.6%) with IAsp ( Figure 1) ; esti- (Table S2 in File S1).
At baseline and week 52, mean PPG increased up to 2 hours after meal consumption in both arms and then started to decrease ( Mean glycated haemoglobin (HbA1c) level over time. Data are mean (SE) for the full analysis set. During run-in, observed mean HbA1c was reduced from 64.0 mmol/mol (8.0%) to 59.7 mmol/mol (7.6%) for participants subsequently randomized to receive mealtime faster aspart (n = 381), and from 64.0 mmol/mol (8.0%) to 59.3 mmol/mol (7.6%) for participants subsequently randomized to receive mealtime insulin aspart (n = 380). Following the 52-week treatment period, observed mean HbA1c was 58.5 mmol/mol (7.5%) with mealtime faster aspart and 59.6 mmol/mol (7.6%) with mealtime insulin aspart. EOT, end of trial; faster aspart, fast-acting insulin aspart FIGURE 2 A, Postprandial plasma glucose (PPG) levels and B, PPG increments based on the meal test at week 52. Data are mean (SE) for the full analysis set. *P = .0054, **P = .0002. Changes from baseline in PPG levels and PPG increments were analysed using a mixed-effect model for repeated measurements. ETD, estimated treatment difference; faster aspart, fast-acting insulin aspart; PG, plasma glucose; PPG, postprandial plasma glucose At baseline, the mean of the 7-9-7-point SMPG profile was 8.7 mmol/L (156.8 mg/dL) in both treatment arms. At 52 weeks, the observed mean of the 7-9-7 point SMPG profile was 8. Figure S4 in File S1).
Based on 7-9-7-point SMPG profiles, mean PPG levels over all meals at week 52 were reduced with faster aspart, and after all individual meals except breakfast with IAsp ( Figure 3 ). Significant treatment differences in favour of faster aspart over IAsp were seen in 2-hour PPG and 2-hour PPG increments for all meals except lunch ( Figure S5 in File S1). (Table S4 in File S1).
Most treatment-emergent adverse events were mild or moderate in severity, with the most common being nasopharyngitis -observed in 128 (33.2%) and 120 (31.6%) participants receiving faster aspart and IAsp, respectively.
Injection-site reactions were reported in 8 participants (2.1%) receiving faster aspart and 5 (1.3%) receiving IAsp (Table S4 in File   S1 ). Seven reactions (5 with faster aspart, 2 with IAsp) were judged as possibly or probably related to bolus insulin, of which 5 were also judged as possibly or probably related to basal insulin.
During the 52-week treatment period, 15 suspected cardiovascular events were referred to an independent external adjudication committee; of these, 5 events in 4 participants were positively adjudicated (Table S5 in File S1). Two events were considered major adverse cardiovascular events (MACE; 1 participant each with stroke and cardiovascular death [both in the IAsp arm]). Two participants in the faster aspart arm had 3 non-MACE events (heart failure, percutaneous revascularization and unstable angina pectoris).
Mean total anti-IAsp (specific and cross-reacting to human insulin) antibody development was similar at baseline and after 12, 26, 40 and 52 weeks of treatment in both treatment arms ( Figure S6 in File S1). No clinically significant differences were seen with regard to vital signs, physical examination, safety laboratory assessments (biochemistry, haematology and lipids) or ECG findings.
| DISCUSSION
In patients with T1D, the insulin profile induced by exogenous rapidacting insulin does not fully control glucose excursions induced by meals, and this mismatch can be exacerbated with varying daily schedules. 4 With regular human insulin, patients are advised to inject at least 30 minutes before meals, but many struggle to adhere to this regimen. 19 Rapid-acting insulin analogues improve control of PPG excursions, 20 can be administered immediately before mealtimes 7 and help improve patients' quality of life 21 ; however, patients often inject rapid-acting insulin analogues during or after meals, [22] [23] [24] even though the action profile of rapid-acting insulin analogues is not fast enough to optimally cover PPG excursions under these circumstances. This has led to development of ultra-fast insulins, for which minor improvements in time of onset can lead to improvements in glycaemic control and treatment flexibility. [8] [9] [10] [11] [12] [13] [14] Overall, the 52-week results from onset 1 are consistent with the initial 26 weeks of the trial, 17 in which faster aspart was associated with significant improvements in HbA1c and improved PPG control in a large patient population. The improvement in PPG control observed with faster aspart relative to IAsp is of particular clinical importance, due to the proposed independent link between PPG and diabetes-related complications. 25 There was no significant difference in overall rates of severe or BG-confirmed hypoglycaemia between treatments; however, as expected, given the faster onset of action with faster aspart, 16 a significantly higher rate of severe or BG-confirmed hypoglycaemia for faster aspart was observed within 1 hour of the start of a meal compared with IAsp. There was no difference at later time points up to 6 hours after starting a meal. Interestingly, there was a trend toward lower incidence of nocturnal hypoglycaemia with faster aspart compared with IAsp.
Strengths of the present trial include its duration, its randomized, double-blind design and the number of participants maintained on therapy for the full 52 weeks. Optimization of basal insulin during the runin period allowed the impact of the two different bolus regimens to be more clearly evaluated. This is the first trial examining long-term treatment in T1D using faster aspart as part of a basal-bolus insulin regimen. In conclusion, the overall safety profile after 52 weeks, including adverse events, immunogenicity, and standard safety variables, was similar between treatment arms and was as expected for IAsp. A statistically significant difference in favour of faster aspart regarding changes in HbA1c level from baseline was maintained over 52 weeks.
Approaching an insulin profile closer to physiological insulin secretion with faster aspart achieves lower PPG and HbA1c levels compared with IAsp, with these clinical improvements achieved alongside increased flexibility in mealtime insulin administration in patients with T1D.
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